Value proposition

Bringing innovative therapies to patients

Draupnir Bio is a Danish biotechnology company driven by a deep commitment to scientific excellence and the desire to bring innovative therapies to patients in need. By harnessing the natural machinery of the lysosome, we are developing oral, small molecule degraders of extracellular pathogenic proteins – the next frontier of targeted protein degradation (TPD), a rapidly emerging field that exploits a cell’s own destruction machinery to tackle disease-causing proteins that have historically been highly challenging to target with conventional therapies. First-generation TPD approaches are exclusively limited to intracellular targets, leaving extracellular and membrane-bound proteins – 40% of the human proteome – untouched. At Draupnir, we are extending the potential of TPD to both extracellular and membrane-bound proteins in a pioneering approach using our novel and differentiated, proprietary technology platform which targets lysosome receptors and has the potential to revolutionise the field of TPD.

Led by a highly experienced team of pharma and biotech industry leaders, Draupnir is a spin-out from Aarhus University, Denmark and the Max-Planck Society, Germany and is backed by a syndicate of leading European investors.

biotechnology, biotech, targeted protein degradation, membrane-bound proteins, extracellular targets, and lysosome